Heart failure & cardiomyopathies
Systematic Review and Meta-Analysis of Intravenous Iron-Carbohydrate Complexes in HF with Reduced Ejection Fraction (HFrEF) Patients with Iron Deficiency
Authors' conclusion
IV iron-carbohydrate therapy resulted in improvements in a range of clinical outcomes and increased functional and exercise capacity, whereas AEs were not significantly different between IV iron-carbohydrate and placebo/standard of care arms.
Study context
- Population
- Patients with HFrEF and iron deficiency/iron deficiency anaemia
- Participants
- 2,381 patients12 randomized controlled trials (RCTs)
- Comparison
- Intravenous (IV) iron-carbohydrate complexes vs placebo/standard of care
- Outcome
- Hospitalization for worsening HF; first hospitalization for worsening HF or death; all-cause mortality
Methodological detailsEmbase (from 1957) and PubMed (from 1989) searched through 25 May 2021
- Embase (from 1957) and PubMed (from 1989) searched through 25 May 2021
Pooled result
As reported in the abstract
Hospitalization for worsening heart failure (HF)
0.53
CI 0.42–0.65P < 0.0001
First hospitalization for worsening HF or death
0.75
CI 0.59–0.95P = 0.016
Further pooled results
Functional and exercise capacity
- Significantly improved vs control
Outcomes by IV iron-carbohydrate formulation
- No significant difference between formulations for similar endpoints
Original publication
Systematic Review and Meta-Analysis of Intravenous Iron-Carbohydrate Complexes in HFrEF Patients with Iron Deficiency. ESC Heart Fail. Published 30 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →